-
Monday, 09/16/2024
Prof. A. Torres Receives the ERS Lifetime Achievement Award in Respiratory Infections
Prof. A. Torres Receives the ERS Lifetime Achievement Award in Respiratory Infections
We are very honored as research fellows in Prof. Torres’ group to announce that last Saturday, he received the ERS Lifetime Achievement Award in Respiratory Infections, granted by the European Respiratory Society. For more information about this award, please follow the link: ERS Award Winners 2024.
-
Friday, 08/16/2024
Launching of the HOMILUNG project website
Last June we launched the website of the Homi-Lung (www.homilung.com) a European project deciphering the causal relationship between cardiovascular and respiratory diseases progression and the immune and microbiome alterations observed during and after pneumonia. It has started in 2024 and it is expected to finish in 2029. Our research group IDIBAPS- Ciberes and Hospital Clinic (Lead by Prof. Antoni Torres) is mainly involved in WP2 (Prospective cohorts and patients need), WP6 (Causal link between pneumonia-induced dysbiosis and CVRD progression in preclinical models) and leads the WP7 (dissemination, communication, and exploitation).
-
Monday, 07/01/2024
Leticia Bueno Receives Nursing Award and Research Grant by the SEPAR (Spanish Society of Pulmonolgy and Thoracic Surgery)
Leticia Bueno has been awarded the 2nd Prize for Best Nursing Communications for the abstract titled "Association Between Malnutrition and Quality of Life in Patients with Bronchiectasis." In addition, she has received the Respira Grant for the Presentation of Communications at the National SEPAR Congress. This recognition highlights Leticia Bueno's significant contributions to nursing research and the impact of nutritional status on patients with bronchiectasis. -
Friday, 06/07/2024
ECCMID CONGRESS 2024, 27-30 April, Barcelona
Our research group has a
-
Friday, 02/02/2024
Ana Motos Awarded the Prestigious RESPIRE - MSCA Fellowship
Dr. Ana Motos, a promising researcher trained in our group in the field of respiratory infections, has been awarded the prestigious RESPIRE - Marie Skłodowska-Curie Actions (MSCA) fellowship. This esteemed grant, funded by the European Respiratory Society and the European Commission, is designed to support groundbreaking research and innovation. Known for its highly competitive selection process, the RESPIRE - MSCA grant provides not only financial support but also access to a vast network of research and training opportunities across Europe.
With the MSCA grant, Dr. Motos will embark on a two-year research journey at the University of Nantes under the supervision of Prof. Antoine Roquilly. Dr. Motos' project, titled "Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures," aims to define sub-phenotypes of respiratory microbiomes associated with the emergence of resistance during treatment and treatment failure. The project's implications extend beyond the scientific community, as findings may contribute to the development of targeted therapeutic approaches for pneumonia, improving patient outcomes, and addressing antibiotic resistance challenges.
-
Thursday, 02/01/2024
Kasra Kiarostami publishes Debut Paper as Lead Author
kasra Kiarostami wants to thanks to Prof. Antoni Torres, Dr. Laia Fernandez, Dr. Ana Motos and all collaborators in the Theravance project the recent article " The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia" was published in International Journal of Antimicrobial Agents journal. The first author is kasra Kiarostami.
In summary, this research compared the efficacy of telavancin and linezolid in addressing biofilms on endotracheal tubes (ETT) in a porcine model simulating methicillin-resistant Staphylococcus aureus (MRSA) ventilator-associated pneumonia (VAP). While MRSA loads on the ETT and cuff did not significantly differ among control, linezolid, and telavancin groups, a notable finding revealed telavancin's ability to reduce MRSA biofilm on the ETT. This suggests potential advantages for telavancin in clinical settings, especially for elective patients. Despite acknowledging the study's limitation of a small sample size, we argue that this model aligns with real-world VAP scenarios in critically ill patients, emphasizing the need for further investigation. The study highlights telavancin's potential significance in combating biofilms and improving treatment approaches for VAP."
Thank you!
-
Thursday, 02/01/2024
New Study Coordinator of the Animal Model
We are delighted to announce that Dr. Flavia Galli has been appointed as the new Research Study Coordinator for our animal model program. With a background in anesthesiology and critical care medicine, Dr. Galli received her medical training at Policlinico Universitario A. Gemelli of Rome, bringing a wealth of expertise to our team.
Over the past two years, Dr. Galli has contributed significantly to our organization as a clinical research fellow, dedicating her efforts to researching the animal model and spearheading projects related to critically ill patients and COVID-19. Her commitment to advancing medical knowledge and improving patient outcomes has been exemplary.
In her new role, Dr. Galli will assume responsibility for the design, implementation, and coordination of animal protocols, ensuring the highest standards of scientific rigor. Additionally, she will oversee the analysis of data and scientific production, driving forward innovative research initiatives.
Furthermore, Dr. Galli will play a pivotal role in facilitating collaboration with incoming international fellows, fostering an environment of knowledge exchange and collaboration.
Congratulations Flavia!
-
Friday, 01/19/2024
New Fellow from Italy
Davide Calabretta, MD
Resident in Anesthesiology and Intensive Care Medicine at the University of Milan.
Staying in IDIBAPS from May 2023 to April 2024.
During his period as a fellow he has been involved in the study of hospital-acquired pneumonia and ventilator-associated pneumonia, investigating the clinical impact of the recommendations of 2017 ERS/ESICM/ESCMID/ALAT guidelines on outcomes and studying new nonpharmacological treatment approaches in the animal model.
-
Friday, 01/19/2024
New Fellow from Italy
Federica Viola Piedepalumbo, MD, pneumology resident at respiratory unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Staying in IDIBAPS from November 2023 to April 2024.
Her research interests are bronchiectasis, mycobacterial diseases, and respiratory infections.
During her period as a fellow, she has been involved in the study of new nonpharmacological treatment approaches in the animal model and in the study of safety of steroids in severe community-acquired pneumonia (CAP).
-
Wednesday, 01/10/2024
SEPAR AWARDS 2023 Leticia Bueno
The Spanish Society of Pulmonology and Thoracic Surgery awarded our research nurse with the "beca becario" and the first SEPAR-CHIESI 2023 award for the best communication in the nursing area.
